Subdural Haematoma Market

Market Overview:

The 7 major subdural haematoma markets are expected to exhibit a CAGR of 3.61% during 2024-2034.

The subdural haematoma market has been comprehensively analyzed in IMARC’s new report titled “Subdural Haematoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Subdural haematoma refers to an accumulation of blood between the dura, the outermost layer of the brain, and the next layer, called the arachnoid. The bleeding rapidly occupies the brain region, thereby compressing brain tissue. This frequently results in brain damage and might even be fatal. The symptoms of subdural haematoma generally fluctuate depending on the pace of the bleeding. Occasionally, the symptoms appear straight away, and sometimes they may take up to two weeks to occur. These indications include drowsiness and disorientation, convulsions, vomiting, speech and cognitive impairments, vision disturbances, losing and regaining consciousness, numbness or weakness that may come and go, and extreme fatigue. A doctor usually performs a computed tomography (CT) or magnetic resonance imaging (MRI) scan to detect a subdural haematoma. Additional tests can also be requested, including a blood test to examine any complications with the clotting and further blood tests to eliminate any other possible reason for the patient's apparent symptoms. A CT angiography may also be carried out to confirm the condition.

The rising incidences of risk factors associated with subdural haematoma, such as the increasing number of head injuries and the growing alcohol abuse, are primarily driving the subdural haematoma market. In addition to this, the escalating utilization of aspirin, anti-inflammatory drugs such as ibuprofen, and anticoagulant medications is also bolstering the market growth. Moreover, the expanding geriatric population, who are more susceptible to brain shrinkage that occurs with aging, is further acting as a significant growth-inducing factor. Subdural haematoma results from bleeding originating from bridging veins, which are prone to injury following acceleration/deceleration movement of the brain. Besides this, the widespread adoption of contrast-enhanced MRI as it can easily detect neomembranes, thick and extensive membranes, and solid clots is also augmenting the global market. Additionally, the emerging popularity of burr-hole evacuation for treating uncomplicated subdural haematoma, which involves drilling one or more small holes in the skull and inserting a flexible rubber tube to drain the clot, is further creating a positive outlook for the market. Apart from this, several key players are making significant investments to better understand the merits and limitations of different surgical techniques, which could eventually help improve the prognosis. This, in turn, is expected to drive the global subdural haematoma market in the coming years.

IMARC Group’s new report provides an exhaustive analysis of the subdural haematoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for subdural haematoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the subdural haematoma market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the subdural haematoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the subdural haematoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current subdural haematoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the subdural haematoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the subdural haematoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the subdural haematoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the size of the subdural haematoma patient pool (​2018-2023​) across the seven major markets?
• What would be the forecasted patient pool (​2024-2034​) across the seven major markets?
• What are the key factors driving the epidemiological trend of subdural haematoma?
• What will be the growth rate of patients across the seven major markets?
   

Subdural Haematoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for subdural haematoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the subdural haematoma market?